Deals & Cases | 22 octobre 2026

Oversubscribed USD 135 Million Series D Financing Round of Nouscom

Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, announced the closing of an oversubscribed EUR 120m (USD 135m ) series D financing round. The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures), and Neva SGR (Intesa Sanpaolo Group). Nouscom’s other existing international life sciences investors, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures, all participated in the round.

Walder Wyss has advised the group of Series D investors. The team was led by Dimitrios Berger (Managing Associate, Corporate/M&A and Venture Capital) and Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital) and further included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) ,Marion Bähler (Partner, Corporate/M&A and Venture Capital), Merens Derungs (Associate, Corporate/M&A and Venture Capital).